Last updated: 2026-09-04 21:28:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
CAMP4 Therapeutics Corporation (CAMP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.42, with a market capitalization of $238.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.44 to $7.75. This page covers its latest market performance, valuation, price trends and company information.
$238.46M | |
$4.45 | |
$801.55 | |
$0.39 | |
$4.49 | |
117.38K | |
-- | |
-- | |
$7.75 | |
$1.44 | |
-- | |
-- |
CAMP4 Therapeutics Corporation (CAMP) is trading at $4.32 in after-hours trading as of 2026-09-04 21:22:00, down 3.90% ($0.17) from the regular-session close of $4.49.
After-hours trading shows how investors are pricing CAMP after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, CAMP4 Therapeutics Corporation (CAMP) moved from $4.18 to $4.42, representing a gain of 5.77% ($0.24).
The stock traded between $4.36 and $4.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong upward.
The average daily volume was 419.69 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 47.2%
CAMP is currently trading at $4.42, placing it 47.2% of the way from its 52-week low of $1.44 to its 52-week high of $7.75. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. The company focuses on genetic diseases of the central nervous system and liver. Its pipeline products include CMP-CPS-001 and CMP-SYNGAP. The company operates as a single operating segment, R&D, which engages in the development of a new class of RNA-based therapeutics to treat a broad range of genetic diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 48 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CAMP4 Therapeutics Corporation (CAMP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.